P194: Persistence of growth promoting effects in children with achondroplasia over seven years: Update from phase II extension study with vosoritide*

• Julie Hoover-Fong,
• Melita Irving,
• Carlos Bacino,
• Joel Charrow,
• Valérie Cormier-Daire,
• Lynda Polgreen,
• Paul Harmatz,
• Alice Huntsman-Labed,
• Elena Fisheleva,
• Ian Sabir,
• Jonathan Day,
• John Phillips,
• Ravi Savarirayan

Affiliations

Julie Hoover-Fong

McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD

Melita Irving

Guy’s and St. Thomas’ NHS Foundation Trust, Evelina Children's Hospital, London, UK

Carlos Bacino

Baylor College of Medicine, Houston, TX

Joel Charrow

Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

Valérie Cormier-Daire

Centre of Reference for Constitutional Bone Diseases (MOC), Department of Clinical Genetics, Paris Centre University, INSERM, Imagine Institute, Necker-Enfants Malades Hospital, Paris, France

Lynda Polgreen

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA

Paul Harmatz

UCSF Benioff Children’s Hospital Oakland, Oakland, CA

Alice Huntsman-Labed

BioMarin (UK) Limited, London, UK

Elena Fisheleva

BioMarin (UK) Limited, London, UK

Ian Sabir

BioMarin (UK) Limited, London, UK

Jonathan Day

BioMarin (UK) Limited, London, UK

John Phillips

Vanderbilt University Medical Center, Nashville, TN

Ravi Savarirayan

Murdoch Children’s Research Institute, Royal Children’s Hospital, and University of Melbourne, Parkville, Victoria, Australia